Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Loading
Start 30 days free, no card. Full Pro access for a month, then decide. Start free
No 8-K events recorded for this window.
AbbVie delivered 12.4% revenue growth to $15 billion with adjusted EPS of $2.65 exceeding guidance by $0.07, driven by exceptional immunology performance as Skyrizi and Rinvoq continued their rapid adoption in IBD and other indications. Neuroscience momentum accelerated across the portfolio while the Crohn's combination platform showed transformational efficacy data. Management raised full-year EPS guidance by $0.12 to $14.08-$14.28 on the strength of the Q1 beat.
Innovation & R&D | Competitive Dynamics | Revenue Growth | Demand | Regulation Policy | M&A | Product Launch | Pricing | |
|---|---|---|---|---|---|---|---|---|
| 2024Q4 | 3 | 3 | 5 | 7 | 2 | 2 | 2 | 4 |
| 2025Q1 | 4 | 4 | 4 | 1 | 5 | 1 | 1 | 2 |
| 2025Q2 | 3 | 4 | 4 | 4 | 1 | 2 | 2 | 1 |
| 2025Q3 | 5 | 4 | 3 | 2 | 4 | 1 | 2 | 2 |
| 2025Q4 | 7 | 5 | 1 | 1 | 2 | 1 | 2 | 1 |
| 2026Q1 | 7 | 5 | 2 | 2 | 3 | 1 |
| '24Q4 | '25Q1 | '25Q2 | '25Q3 | '25Q4 | '26Q1 | |
|---|---|---|---|---|---|---|
| Innovation & R&D | 3 | 4 | 3 | 5 | 7 | 7 |
| Competitive Dynamics | 3 | 4 | 4 | 4 | 5 | 5 |
| Revenue Growth | 5 | 4 | 4 | 3 | 1 | 2 |
| Demand | 7 | 1 | 4 | 2 | 1 | 2 |
| Regulation Policy | 2 | 5 | 1 | 4 | 2 | |
| M&A | 2 | 1 | 2 | 1 | 1 | 3 |
| Product Launch | 2 | 1 | 2 | 2 | 2 | 1 |
| Pricing | 4 | 2 | 1 | 2 | 1 |
What ABBV and other companies said about each other on FY2026 Q1 earnings calls — extracted verbatim from public transcripts. Mentions from the newest quarter are a Pro feature.
“including one with Castro Therapeutics, we recently began a Phase I study”
AbbVie is collaborating with Castro Therapeutics on an early-stage solid-tumor program (a pan-KRAS inhibitor), part of its external-innovation investments.
“closing the Remagen agreement, giving us a novel PD-1 VEGF bispecific antibody”
AbbVie expanded its oncology pipeline by closing a deal for a PD-1 VEGF bispecific antibody, signaling continued external sourcing of oncology assets.
“the Capstan acquisition with the B-cell depletion approach with the in vivo CAR-T platform”
AbbVie highlights its Capstan acquisition and its in vivo CAR-T B-cell depletion platform as a pillar of its long-term immunology pipeline.
“We acquired Nimble to give us the oral peptides capability.”
AbbVie cites its acquisition of Nimble as adding an oral peptides capability central to its future immunology combination strategy.
The table scrolls sideways. Swipe it, or select it and use the arrow keys.
| Quarter | Revenue | Rev YoY | EPS | EPS YoY | Gross margin | Op margin | Net margin | FCF |
|---|---|---|---|---|---|---|---|---|
| FY2024 Q4 | $15.10B | +5.6% | $-0.02 | -103.9% | 70.9% | -9.9% | -0.1% | $6.76B |
| FY2025 Q1 | $13.34B | +8.4% | $0.72 | -6.5% | 70.0% | 28.0% | 9.6% | $1.40B |
| FY2025 Q2 | $15.42B | +6.6% | $0.53 | -31.2% | 71.8% | 31.7% | 6.1% | $4.88B |
| FY2025 Q3 | $15.78B | +9.1% | $0.10 | -88.7% | 66.4% | 12.1% | 1.2% | $7.53B |
| FY2025 Q4 | $16.62B | +10.0% | $1.02 | +5735.4% | 72.6% | 35.0% | 10.9% | $4.89B |
| FY2026 Q1Selected | $15.00B | +12.4% | $0.39 | -45.8% | 71.9% | 31.6% | 4.7% | $3.56B |
| FY2026 Q2 | $16.99B | +10.2% | $2.04 | +284.9% | 84.7% | 39.6% | 21.3% | — |
Management’s own words, often on a non-GAAP, constant-currency, or adjusted basis — so these can differ from the GAAP figures above (e.g. constant-currency revenue growth excludes currency swings).
Calendar quarter Q1 2026Earnings call Apr 29, 2026
FY2026 Q1 in brief
AbbVie delivered 12.4% revenue growth to $15 billion with adjusted EPS of $2.65 exceeding guidance by $0.07, driven by exceptional immunology performance as Skyrizi and Rinvoq continued their rapid adoption in IBD and other indications.
Newest quarter FY2026 Q2 is part of Pro · see what Pro adds →
GAAP revenue YoY +12.4% → base 7. The base score is anchored to the GAAP revenue YoY band before transcript, EPS, and guidance adjustments.
Sources. Tellvest earnings-call sentiment score for AbbVie (ABBV), FY2026 Q1: 9/10. Scores: AbbVie’s public earnings-call transcripts and SEC-reported results — the base band is anchored to reported GAAP revenue growth; transcript, EPS and guidance adjustments are applied separately (documented exceptions apply to a few issuers). Price: ABBV daily closing prices for the trailing year; dots mark earnings calls, colored by that quarter’s score; the newest quarter’s score is part of Tellvest Pro. How to read a company earnings-call score.
Percentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions.
| Analyst | Firm | Questions · challengingPercentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions. |
|---|---|---|
| Chris Schott | JPMorgan | 10 questions · 0% challenging |
| Steve Scala | TD Cowen | 8 questions · 63% challenging |
| Terence Flynn | Morgan Stanley | 7 questions · 14% challenging |
| Mohit Bansal | Wells Fargo | 7 questions · 14% challenging |
| Dave Risinger | Leerink Partners | 7 questions · 0% challenging |
| Vamil Divan | Guggenheim | 6 questions · 17% challenging |
| Asad Haider |
| Goldman Sachs |
| 6 questions · 17% challenging |
| David Amsellem | Piper Sandler | 4 questions · 0% challenging |
| Geoff Meacham | Citigroup | 4 questions · 0% challenging |
| Trung Huynh | RBC Capital Markets | 3 questions · 0% challenging |
| Firm | Analysts | Questions · challengingPercentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions. |
|---|---|---|
| JPMorgan | 1 analyst | 10 questions · 0% challenging |
| TD Cowen | 1 analyst | 8 questions · 63% challenging |
| Wells Fargo | 1 analyst | 7 questions · 14% challenging |
| Leerink Partners | 1 analyst | 7 questions · 0% challenging |
| Goldman Sachs | 2 analysts | 7 questions · 14% challenging |
| Morgan Stanley | 1 analyst | 7 questions · 14% challenging |
| Guggenheim | 1 analyst | 6 questions · 17% challenging |
| Citigroup | 1 analyst | 4 questions · 0% challenging |
| Company | Score | Trend | Rev YoY |
|---|---|---|---|
ABBV AbbVie | 9 | +12.4% | |
| AMGN Amgen Inc. | 8 | +5.8% | |
| BIIB Biogen | 2 | +1.9% | |
| BMY Bristol Myers Squibb | 4 | +2.6% | |
| GILD Gilead Sciences | 8 | +4.4% | |
| JNJ Johnson & Johnson | 7 | +9.9% | |
| LLY Lilly (Eli) | 10 | +55.5% | |
| MRK Merck & Co., Inc. | 7 | +4.3% | |
| PFE Pfizer | 5 | +5.4% |